|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
Blood, 15 June 2007, Vol. 109, No. 12, pp. 5164-5167. Prepublished online as a Blood First Edition Paper on March 6, 2007; DOI 10.1182/blood-2007-01-069831.
CLINICAL TRIALS AND OBSERVATIONS Long-term disease-free survivors with cytogenetically normal acute myeloid leukemia and MLL partial tandem duplication: a Cancer and Leukemia Group B study1 Division of Hematology and Oncology, Department of Internal Medicine, Comprehensive Cancer Center, The Ohio State University, Columbus; 2 The Cancer and Leukemia Group B (CALGB) Statistical Center, Duke University Medical Center, Durham, NC; 3 Division of Human Cancer Genetics, Department of Microbiology, Virology, Immunology, and Medical Genetics, Comprehensive Cancer Center, The Ohio State University, Columbus; 4 Charité, Campus Benjamin Franklin, Medizinische Klinik III, Berlin, Germany; 5 Section on Hematology and Oncology, Comprehensive Cancer Center of Wake Forest University, Winston-Salem, NC; 6 University of Alabama at Birmingham; 7 North Shore University Hospital, Manhasset, NY; 8 University of Chicago, IL
The clinical impact of MLL partial tandem duplication (MLL-PTD) was evaluated in 238 adults aged 18 to 59 years with cytogenetically normal (CN) de novo acute myeloid leukemia (AML) who were treated intensively on similar Cancer and Leukemia Group B protocols 9621 and 19808. Twenty-four (10.1%) patients harbored an MLL-PTD. Of those, 92% achieved complete remission (CR) compared with 83% of patients without MLL-PTD (P = .39). Neither overall survival nor disease-free survival significantly differed between the 2 groups (P = .67 and P = .55, respectively). Thirteen MLL-PTD+ patients relapsed within 1.4 years of achieving CR. MLL-PTD+ patients who relapsed more often had other adverse CN-AML–associated molecular markers. In contrast with previously reported studies, 9 (41%) MLL-PTD+ patients continue in long-term first remission (CR1; range, 2.5-7.7 years). Intensive consolidation therapy that included autologous peripheral stem-cell transplantation during CR1 may have contributed to the better outcome of this historically poor-prognosis group of CN-AML patients with MLL-PTD.
The MLL partial tandem duplication (MLL-PTD) produces an in-frame, elongated protein and occurs in approximately 8% of patients with cytogenetically normal (CN) acute myeloid leukemia (AML).1 The MLL-PTD affects only 1 allele in CN-AML, and the second, wild-type (WT), MLL allele is silenced.2 Unlike MLL chimeric fusion proteins arising from translocations involving 11q23, the MLL-PTD protein retains the C-terminal domains including the histone H3 lysine 4 methyltransferase activity.3 In a murine knock-in model, the Mll-PTD acts as a gain-of-function allele, giving rise to aberrations in skeletal development and conferring proliferation and self-renewal advantages to hematopoietic stem/progenitor cells without causing frank leukemia.4 The MLL-PTD was the first adverse prognostic molecular marker identified in CN-AML.5,6 In several subsequent studies, the presence of MLL-PTD was associated with a shorter remission duration, with most patients relapsing within 1 year.7–10 We report herein for the first time that younger adults with MLL-PTD (MLL-PTD+) treated on 2 recent frontline Cancer and Leukemia Group B (CALGB) protocols had a clinical outcome comparable to that of CN-AML patients without MLL-PTD (MLL-PTD–) and that a substantial percentage of MLL-PTD+ patients are disease-free beyond 2.5 years.
A combination of real-time reverse transcriptase–polymerase chain reaction (RT-PCR) and nested RT-PCR/sequencing was used to detect MLL-PTD in pretreatment bone marrow (BM) or blood (PB) samples as previously described.2,7 All patients gave informed consent for the research use of their specimens, in accordance with the Declaration of Helsinki. The clinical trials and companion protocols were approved by the Ohio State University Institutional Review Board and the Cancer and Leukemia Group B. Screening was conducted as described previously for additional molecular markers associated with CN-AML (ie, FLT3 internal tandem duplication [FLT3-ITD], FLT3 tyrosine kinase domain [FLT3-TKD] mutation, NPM1 mutation, and high BAALC and ERG expression).11–14 All screening assays were performed at The Ohio State University Comprehensive Cancer Center. Patients enrolled on CALGB 9621 and 19808 received induction treatment that included cytarabine, etoposide, and daunorubicin with or without PSC-833, a multi-drug resistance protein inhibitor also called valspodar. Patients who achieved complete remission (CR) underwent autologous peripheral blood stem-cell transplantation (auto-PBSCT) phase.15,16 Clinical end points were disease-free survival (DFS) and overall survival (OS), as defined previously.14 Pretreatment clinical features were compared between the MLL-PTD+ and MLL-PTD– groups as well as between MLL-PTD+ patients who did and those who did not relapse using Fisher 2-sided exact and Wilcoxon rank sum tests for categoric and continuous variables, respectively. Estimatedprobabilities of DFS and OS were calculated using the Kaplan-Meier method, and the log-rank test evaluated differences between survival distributions. All analyses were performed by the CALGB Statistical Center.
Of the 238 CN-AML patients, 24 (10.1%) harbored an MLL-PTD, which represents the largest series of MLL-PTD+ CN-AML patients treated similarly and with outcome reported. MLL-PTD+ patients differed from MLL-PTD– patients with respect to white blood cell (WBC) counts (median, 4.35 vs 25.15 X109/L; P < .001), extramedullary involvement (9% vs 31%; P = .03), and French-American-British (FAB) subgroups (P = .04); a higher percentage of FAB M2 (48% vs 32%) and a lower percentage of FAB M4/M5 (10% vs 35%) was observed in the MLL-PTD+ group (Table 1). Among patients with available tissue, MLL-PTD+ patients more often presented with wild-type NPM1 (NPM1-WT; 76% vs 32%; P < .001) and high BAALC expression (81% vs 46%; P = .009). In contrast, there was no significant association between the MLL-PTD status and the presence of FLT3-ITD (P = .37); 25% and 35% of MLL-PTD+ and MLL-PTD– patients, respectively, had FLT3-ITD (Table 1).
CR rates were not significantly different between the MLL-PTD+ and MLL-PTD– patients (92% vs 83%; P = .39; Table 1). The CR rate for MLL-PTD+ patients was similar to that reported in a German study (Döhner et al9) that administered idarubicin, cytarabine, and etoposide–based intensive double-induction therapy, and higher than CR rates observed in other studies (Table S1, available on the Blood website; see the Supplemental Materials link at the top of the online article).7,8,17 Younger age (< 60 years) and/or inclusion of etoposide may have contributed to the high CR rates in the CALGB and German studies. With a median follow-up of 4.7 years, no significant differences in DFS (P = .55) or OS (P = .67) between MLL-PTD+ and MLL-PTD– patients were observed (Table 1). The estimated 3-year DFS and OS rates for MLL-PTD+ patients were, respectively, 41% and 50% compared with, respectively, 48% and 52% for MLL-PTD– patients (Table 1). Most striking was that 50% of MLL-PTD+ patients were alive at last follow-up and 9 (41%) of 22 were still in first CR (CR1), ranging from 2.2 to 7.7 years (Figure 1). This is markedly different from data previously reported, where few adult MLL-PTD+ patients maintained a remission beyond 2 years (Table S1). In the Döhner et al9 study, CN-AML patients aged 16 to 60 years in CR1 were treated with a high-dose cytarabine and mitoxantrone-based (HAM) regimen for the first consolidation therapy and yet 11 of 16 MLL-PTD+ patients relapsed within 2 years, and the 5 patients remaining in CR1 were censored with short follow-ups, from only a few months to about a year after achieving remission. Two patients in the Döhner et al9 study, who achieved a second CR and received allogeneic transplantation, were alive with approximately 3 and a half to 4 years of follow-up. In the current study, 18 of 22 MLL-PTD+ patients in CR1 underwent auto-PBSCT, which may have contributed to the reduced number of early relapses in our patients with MLL-PTD+ CN-AML. Three of the other 4 received multiple courses of high-dose cytarabine and 1 received 1 course of high-dose cytarabine before refusing further treatment.
Although a considerable fraction of MLL-PTD+ patients were alive and relapse-free, the majority relapsed within the first 1.4 years of remission (Figure 1). Thus, we analyzed the MLL-PTD+ group for pretreatment and/or molecular characteristics that might explain some of the differences in outcome in this subgroup. Relapsed patients had a higher percentage of BM blasts at diagnosis (median, 66% vs 40.5%; P = .03) and more often were high BAALC expressers (P = .03; Table 1). Nine of 11 MLL-PTD+ patients with high BAALC relapsed, whereas all 3 patients with low BAALC remain in remission (Figure S1A). While not statistically significant, the presence of other adverse molecular prognostic markers was also more frequent among relapsed MLL-PTD+ patients compared with MLL-PTD+ patients who remain in remission. Thirty-eight percent of the relapsed patients had FLT3-ITD compared with only 11% of those still in CR1. Similar trends were observed for NPM1-WT and high ERG expression. Among relapsed MLL-PTD+ patients evaluated for NPM1 mutations and ERG expression, 9 of 10 had only NPM1-WT alleles and 3 of 8 were high ERG expressers. In contrast, among MLL-PTD+ patients remaining in remission, 3 of 6 carried NPM1 mutations and 0 of 5 were high ERG expressers (Table 1; Figure S1B-D). In conclusion, we have observed for the first time a relatively good outcome for MLL-PTD+ patients who achieved CR, with 41% of such patients remaining in first remission beyond 2.5 years. This contrasts with previous studies reporting only a few patients who achieved long-lasting remissions. Besides the multitude of other potential factors, we postulate that treatment advances for younger adults may have contributed to the better outcome observed for the MLL-PTD+ patients reported in this study. Although these are encouraging findings, it is clear that the majority of MLL-PTD+ patients still relapse early. Our data suggest that the presence of additional, negative prognostic markers may be a contributing factor. Larger studies are necessary to confirm our results and to elucidate the underlying mechanisms of leukemogenesis, which could lead to the development of molecularly targeted curative therapies.
Contribution: S.P.W., A.S.R., G.M., K.M., and C. D. Bloomfield contributed to the design and analysis of this study. S.P.W., A.S.R., G.M., K.M., P.P., and C. D. Bloomfield contributed to the writing of this manuscript and all authors agreed on the final version. S.P.W., P.P., C.L., C. D. Baldus, J.W., and T.V. carried out laboratory-based research. A.S.R. performed statistical analyses. B.L.P., A.J.C., J.E.K., R.A.L., M.A.C., G.M., and C. D. Bloomfield were involved directly or indirectly in care of patients and/or sample procurement. Conflict-of-interest disclosure: The authors declare no competing financial interests. A complete list of the members of the CALGB study group can be found in Document S1, available on the Blood website; see the Supplemental Materials link at the top of the online article. Correspondence: Susan P. Whitman, Comprehensive Cancer Center and James Cancer Hospital and Solove Research Institute, The Ohio State University, 2001 Polaris Parkway, Columbus, OH 43240; e-mail: susan.whitman{at}osumc.edu.
We thank Ms Donna Bucci of the CALGB Leukemia Tissue Bank and the Ohio State University Comprehensive Cancer Center's Nucleic Acid Shared Resource for technical support. We thank CALGB-participating institutions, medical professionals, and AML patients for their valuable involvement with this study. This work was supported in part by National Institutes of Health (NIH) grants CA101140, CA77658, CA16058, CA102031, CA096887, CA089341, CA41287, and CA098933 and the Coleman Leukemia Research Foundation.
Submitted January 23, 2007; accepted February 20, 2007.
Prepublished online as Blood First Edition Paper, March 6, 2007
DOI: 10.1182/blood-2007-01-069831
The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 USC section 1734.
  CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
 |
 |
|||||||
 |
 |
 |
 |
 |
 |
 |
 |
||
| Copyright © 2007 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||
Top
Abstract
Introduction
